Korean J Urol.  2013 Sep;54(9):619-623.

Serum Total Testosterone Level and Identification of Late-Onset Hypogonadism: A Community-Based Study

• Kang S
• Park HJ
• Park NC

Abstract

PURPOSE
Late-onset hypogonadism (LOH) in aging males is a clinical and biochemical syndrome characterized by a decline in serum testosterone levels. LOH results in various physical and mental disabilities. We evaluated the relationship between serum testosterone levels and symptoms of LOH.
MATERIALS AND METHODS
During an andropause screening program, we examined responses to the Saint Louis university androgen deficiency in aging males (ADAM) questionnaire and results on the International Index of Erectile Function (IIEF-5) in terms of clinical symptoms and evaluated serum total testosterone levels for a biochemical diagnosis of LOH in healthy community-living volunteers aged over 40 years.
RESULTS
The mean age of the 534 men was 59.1 years (range, 40 to 79 years), and their mean serum testosterone level was 464.1+/-171.9 ng/dL. The serum testosterone level decreased significantly with age. There was a 92.5% positive response rate to the ADAM questionnaire. The percentage of patients whose serum testosterone level was <350 ng/dL among those with a positive response to the ADAM questionnaire was 25.6% (137 patients). The mean serum testosterone level among patients with a positive or negative ADAM questionnaire was 472.4+/-198.5 ng/dL and 487.3+/-165.7 ng/dL, respectively (p>0.05). There was no significant correlation between IIEF-5 scores and serum testosterone levels.
CONCLUSIONS
Among men over 40 years of age, 25.6% met the clinical and biochemical diagnostic criteria for LOH. There was no relationship between serum testosterone levels and symptoms of LOH.

Keyword

Aging; Andropause; Testosterone

MeSH Terms

Aged
Aging
Andropause
Humans
Hypogonadism
Male
Mass Screening
Testosterone
Testosterone

Figure

• 

  FIG. 1 Serum total testosterone level according to age. r2=0.009, p=0.04.

• 

  FIG. 2 International index of erectile function (IIEF-5) score according to total testosterone level. r2=0.004, p=0.112.

Reference

1. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab. 1995; 80:2394–2403.

2. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991; 73:1016–1025.

3. Werner AA. The male climacteric: report of two hundred and seventy-three cases. J Am Med Assoc. 1946; 132:188–194.

4. Kim SW, Oh SJ, Paick JS, Kim SC. Development of the Korean-translation of androgen deficiency in aging males (ADAM) questionnaire. Korean J Urol. 2004; 45:674–679.

5. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000; 49:1239–1242.

6. Ahn TY, Lee DS, Kang WC, Hong JH, Kim YS. Validation of an abridged Korean version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Korean J Urol. 2001; 42:535–540.

7. Basar MM, Aydin G, Mert HC, Keles I, Caglayan O, Orkun S, et al. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology. 2005; 66:597–601.

8. Christ-Crain M, Mueller B, Gasser TC, Kraenzlin M, Trummler M, Huber P, et al. Is there a clinical relevance of partial androgen deficiency of the aging male? J Urol. 2004; 172:624–627.

9. Lin YC, Hwang TI, Chiang HS, Yang CR, Wu HC, Wu TL, et al. Correlations of androgen deficiency with clinical symptoms in Taiwanese males. Int J Impot Res. 2006; 18:343–347.

10. Tancredi A, Reginster JY, Schleich F, Pire G, Maassen P, Luyckx F, et al. Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol. 2004; 151:355–360.

11. Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function. World J Urol. 1997; 15:21–26.

12. Morales A, Johnston B, Heaton JP, Lundie M. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol. 1997; 157:849–854.

13. Schiavi RC, Schreiner-Engel P, Mandeli J, Schanzer H, Cohen E. Healthy aging and male sexual function. Am J Psychiatry. 1990; 147:766–771.

14. Park JS, Hong JI, Park NC. Changes in the quality of life after tansdermal testosterone (androderm) supplement therapy in the aging male. Korean J Urol. 1999; 40:1057–1065.

15. Park NC, Yan BQ, Chung JM, Lee KM. Oral testosterone decanoate (andriol) supplement therapy improve the quality of life in the men with testosterone deficiency. Korean J Androl. 2002; 20:34–44.

16. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994; 78:1360–1367.

17. de Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev. 1995; 16:63–86.

18. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008; 159:507–514.

19. Heinemann LA, Saaf F, Thiele K, Woods-Duphenee S. The aging male's symptom rating scale: Cultural and linguistic validation into English. Aging Male. 2001; 4:14–22.

20. Korenman SG, Morley JE, Mooradian AD, Davis SS, Kaiser FE, Silver AJ, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab. 1990; 71:963–969.

21. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994; 151:54–61.

22. Carani C, Scuteri A, Marrama P, Bancroft J. The effects of testosterone administration and visual erotic stimuli on nocturnal penile tumescence in normal men. Horm Behav. 1990; 24:435–441.

23. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000; 85:2839–2853.